PD-1/PD-L1: Immune checkpoint signaling balance and differential mechanisms of action of inhibitors
This article focuses on the molecular characteristics of the PD-1/PD-L1 immune checkpoint pathway and the mechanisms of action of its inhibitors, systematically elaborating the balance between T cell activation signals and inhibitory signals and the "brake" functional positioning of immune checkpoints, analyzing the differences between PD-1 and PD-L1 in expressing cell types and induction conditions as well as the molecular pathways by which tumor cells utilize this pathway to achieve immune evasion, and comparing the systematic differences between PD-1 inhibitors and PD-L1 inhibitors in antibody structure, mechanisms of action, and adverse reaction risks.
- Recent Advances
- Product Information
Recent Advances
PD-1/PD-L1: Immune Checkpoint Signal Balance and the Differential Mechanisms of Action of Inhibitors
Brief Introduction: This article focuses on the molecular characteristics of the PD-1/PD-L1 immune checkpoint pathway and the mechanisms of action of its inhibitors, systematically elaborating on the balance between T cell activation signals and inhibitory signals and the "brake" functional positioning of immune checkpoints, analyzing the differences between PD-1 and PD-L1 in expressing cell types and induction conditions as well as the molecular pathways by which tumor cells utilize this pathway to achieve immune evasion, and comparing the systematic differences between PD-1 inhibitors and PD-L1 inhibitors in antibody structure, mechanisms of action, and adverse reaction risks.
I. The Dual Functions of the Immune System and the Signal Balance of T Cells.
The human body has a complete self-protection system called the immune system, which can eliminate "foreign" components in the body, such as tumor cells, viruses, and bacteria, while avoiding damage to its own tissues and organs. In the immune system, T cell-mediated cellular immunity is the "main force" for eliminating tumors. T cells need to be activated to exert anti-tumor effects, and the magnitude and quality of T cell activation depend on the balance between activation signals and inhibitory signals——activating antibodies emit activation signals like the accelerator of a car, while inhibitory antibodies emit inhibitory signals like stepping on the brake. Immune checkpoints can be regarded as the brake system of immune cells, referring to a series of molecules expressed on immune cells that can regulate the degree of immune activation, keeping the activation level of T cells within a normal range and preventing damage to the body's healthy tissues. PD-1/PD-L1 and CTLA-4 are the immune checkpoints most familiar to us at present. This "accelerator—brake" balance framework is the foundation for understanding the physiological functions and pathological significance of the PD-1/PD-L1 pathway.
II. The Molecular Pathway by Which Tumor Cells Utilize PD-L1 to Achieve Immune Evasion.
Our body possesses the ability to self-eliminate tumors, but there are always some "cunning" tumor cells that can escape immune surveillance and grow recklessly, harming the health of the body. Tumor cells precisely exploit the characteristics of immune checkpoints: tumor cells express PD-L1 protein on their surface, causing T cells to lose the activity to kill tumor cells, thereby achieving immune evasion. From a mechanistic analysis, after PD-L1 binds to PD-1 on the surface of T cells, the inhibitory motif in the intracellular domain of PD-1 is phosphorylated, recruiting protein tyrosine phosphatases to dephosphorylate key kinases in the T cell receptor signaling pathway, thereby blocking downstream signal transduction and ultimately leading to T cell proliferation arrest, reduced secretion of effector cytokines, and loss of cytotoxic function. It is through this mechanism that tumor cells convert T cells that should attack them into a functionally exhausted state.
III. Expression Characteristics and Regulatory Differences of PD-1 and PD-L1.
PD-1 is programmed death receptor 1, an immune checkpoint receptor expressed by activated T cells and an important immunosuppressive molecule. PD-1 regulates the immune system and promotes self-tolerance by downregulating the immune system's response to human cells and by inhibiting T cell inflammatory activity. This can prevent autoimmune diseases, but it can also prevent the immune system from killing cancer cells. PD-1 can be expressed on the surface of immune cells such as T cells and B cells. However, when T cells are not activated, PD-1 is almost not expressed; only after T cell activation is PD-1 expressed on the surface of T cells——this "activation-induced expression" characteristic means that inhibition of the PD-1 pathway mainly acts on immune responses that have already been initiated.
In addition to being expressed on the tumor surface to participate in immune evasion, PD-L1 is also expressed on the surface of antigen-presenting cells such as DC cells and macrophages, as well as vascular endothelial cells, under IFN-γ stimulation. This "inflammation-induced expression" pattern means that the expression level of PD-L1 is closely related to the inflammatory state of the tumor microenvironment, and also constitutes the biological basis for using PD-L1 expression as a predictive biomarker of efficacy. The differences in expression regulation between the two determine that inhibition of the PD-1 pathway acts more on the T cell side, while blockade of PD-L1 simultaneously involves two sources: tumor cells and antigen-presenting cells.
IV. The Mechanism of Action of PD-1/PD-L1 Inhibitors.
Therapy blocking the PD-1/PD-L1 pathway has become the focus of cancer immunotherapy. PD-1 monoclonal antibodies and PD-L1 monoclonal antibodies are drugs used for cancer immunotherapy. PD-1 monoclonal antibodies or PD-L1 monoclonal antibodies block the binding of PD-1 to PD-L1, restore T cell anti-tumor activity, activate T cells, and kill tumor cells. Once the anti-tumor immune cycle is established, a durable anti-tumor effect can be produced. Currently, multiple PD-1 inhibitors/PD-L1 inhibitors have been approved for marketing in China. From the perspective of intervention mode, the essence of this class of drugs is spatial blockade——antibodies occupy the ligand-receptor binding interface, preventing negative signals from being transmitted, thereby releasing the inhibition of T cell activation.
V. Systematic Differences Between PD-1 Inhibitors and PD-L1 Inhibitors.
Although the two classes of drugs act on the same pathway, they exhibit systematic differences across multiple dimensions.
In terms of drug structure, most PD-1 inhibitors are IgG4 antibodies, with T cells as the target cells, affecting the function of immune T cells. The IgG4 antibody structure has poor stability, so almost all PD-1 inhibitors have been modified to increase stability, and imperfect modifications may lead to the occurrence of adverse reactions. Most PD-L1 inhibitors are IgG1 antibodies, with tumor cells as the target cells, affecting tumor cells. IgG1 monoclonal antibodies are the most commonly used monoclonal antibodies, with a long half-life and good stability. This structural difference determines the pharmacokinetic characteristics and effector function profiles of the two classes of drugs.
In terms of mechanism of action, PD-1 inhibitors bind to PD-1 on the surface of T cells, blocking the binding of PD-1 to PD-L1/PD-L2, relieving the inhibition of T cell activation and proliferation, keeping tumor-specific T cells in an activated state, and restoring the killing function of T cells; however, PD-1 inhibitors simultaneously block the binding of PD-1 on the surface of T cells to PD-L1 and PD-L2 on the surface of immune cells, increasing the risk of potential autoimmune reactions. Compared with PD-1 inhibitors, PD-L1 inhibitors simultaneously bind to PD-L1 on the surface of tumor cells and antigen-presenting cells, resulting in stronger overall immune efficacy, restoring T cell-mediated anti-tumor immune effects, and not affecting the physiological function of PD-L2; PD-L1 inhibitors have the ability to block the binding of PD-L1 on the surface of tumor cells to B7-1 on the surface of T cells, which is conducive to comprehensively activating T cells; in addition, the B7-1 molecule on the surface of dendritic cells binds to the PD-L1 highly expressed on themselves, making it difficult to bind CD28 to initiate immune activation. PD-L1 inhibitors relieve the self-inhibition of DC cells, further strengthening the anti-tumor immune response; PD-L1 monoclonal antibodies selectively block the binding of PD-L1 to PD-1, preserving the function of macrophage PD-L2 and avoiding the occurrence of side effects such as interstitial lung disease. The core of this mechanistic difference lies in the fact that PD-1 inhibitors block all interactions between PD-1 and its two ligands, while PD-L1 inhibitors only block the PD-L1 side, preserving the physiological function of PD-L2.

VI. Conclusion.
As the most representative pathway in the immune checkpoint family, PD-1/PD-L1 constitutes the core target of tumor immunotherapy by virtue of the "accelerator—brake" balance between T cell activation signals and inhibitory signals, the differentiated regulatory patterns of activation-induced PD-1 expression and inflammation-induced PD-L1 expression, and the molecular pathway by which tumor cells achieve immune evasion through the binding of PD-L1 to PD-1.
VII. Common Questions and Product Information on PD-1/PD-L1 Binding Activity Detection
To facilitate researchers and drug development teams in searching for evaluation schemes and product information for PD-1/PD-L1 interactions, this section answers common questions about PD-1/PD-L1 binding activity detection in a Q&A format and provides the product positioning and applicable scenarios of the UniOne® TR-FRET Human PD1/PD-L1 Binding Kit.
Question 1: What methods are used to detect the binding activity of PD-1/PD-L1?
Currently, in vitro methods for evaluating the interaction between PD-1 and PD-L1 proteins mainly include enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR) and biolayer interferometry (BLI), cell-based reporter gene systems, and time-resolved fluorescence resonance energy transfer (TR-FRET). Among them, TR-FRET completes the binding reaction in a homogeneous solution without coating and washing steps, and can directly read the energy transfer signal between the donor and acceptor in a multi-well plate system, making it more suitable for quantitative analysis of PD-1/PD-L1 binding activity and high-throughput screening.
Currently, in vitro methods for evaluating the interaction between PD-1 and PD-L1 proteins mainly include enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR) and biolayer interferometry (BLI), cell-based reporter gene systems, and time-resolved fluorescence resonance energy transfer (TR-FRET). Among them, TR-FRET completes the binding reaction in a homogeneous solution without coating and washing steps, and can directly read the energy transfer signal between the donor and acceptor in a multi-well plate system, making it more suitable for quantitative analysis of PD-1/PD-L1 binding activity and high-throughput screening.
Question 2: How does TR-FRET reflect the activity of PD-1/PD-L1 blocking antibodies?
In the TR-FRET system, the donor (Eu-labeled anti-Tag1 antibody) and the acceptor (Ac-labeled anti-Tag2 antibody) bind to Tag1-PD-L1 and Tag2-PD1 proteins, respectively. When the two proteins bind, the distance shortens and an energy transfer signal is generated, with the acceptor antibody specifically emitting a signal at 665 nm wavelength. After adding PD-1 or PD-L1 blocking antibodies, the antibodies competitively occupy the ligand-receptor binding interface, the formed binding complexes decrease, and the TR-FRET signal decreases with increasing antibody concentration; by plotting the signal inhibition rate against the concentration of candidate molecules, the half-maximal inhibitory concentration (IC50) can be fitted to compare blocking ability and rank candidate molecules. The kit uses Pembrolizumab as a positive control to facilitate verification of the reliability of the experimental system.
In the TR-FRET system, the donor (Eu-labeled anti-Tag1 antibody) and the acceptor (Ac-labeled anti-Tag2 antibody) bind to Tag1-PD-L1 and Tag2-PD1 proteins, respectively. When the two proteins bind, the distance shortens and an energy transfer signal is generated, with the acceptor antibody specifically emitting a signal at 665 nm wavelength. After adding PD-1 or PD-L1 blocking antibodies, the antibodies competitively occupy the ligand-receptor binding interface, the formed binding complexes decrease, and the TR-FRET signal decreases with increasing antibody concentration; by plotting the signal inhibition rate against the concentration of candidate molecules, the half-maximal inhibitory concentration (IC50) can be fitted to compare blocking ability and rank candidate molecules. The kit uses Pembrolizumab as a positive control to facilitate verification of the reliability of the experimental system.
Question 3: What is the UniOne® TR-FRET Human PD1/PD-L1 Binding Kit?
The UniOne® TR-FRET Human PD1/PD-L1 Binding Kit (Catalog No. UA086026) is a homogeneous TR-FRET binding activity detection kit provided by UA-Bio, with human PD-1 and PD-L1 proteins as core reagents, used for quantitative analysis of the binding activity of PD-1 and PD-L1 and evaluation of the blocking ability of antibodies or candidate molecules on this interaction. This product adopts a homogeneous operation workflow without washing steps, has high signal-to-noise ratio, and can directly reflect the competitive inhibition of ligand-receptor binding by antibodies. The kit contains Pembrolizumab positive control, Tag1-PD-L1 protein, Tag2-PD1 protein, Anti-Tag1 Eu antibody, Anti-Tag2 Ac antibody, and Detection buffer as a complete set of components.
The UniOne® TR-FRET Human PD1/PD-L1 Binding Kit (Catalog No. UA086026) is a homogeneous TR-FRET binding activity detection kit provided by UA-Bio, with human PD-1 and PD-L1 proteins as core reagents, used for quantitative analysis of the binding activity of PD-1 and PD-L1 and evaluation of the blocking ability of antibodies or candidate molecules on this interaction. This product adopts a homogeneous operation workflow without washing steps, has high signal-to-noise ratio, and can directly reflect the competitive inhibition of ligand-receptor binding by antibodies. The kit contains Pembrolizumab positive control, Tag1-PD-L1 protein, Tag2-PD1 protein, Anti-Tag1 Eu antibody, Anti-Tag2 Ac antibody, and Detection buffer as a complete set of components.
Question 4: What experimental scenarios is this kit suitable for?
The main application scenarios of this product include: quantitative analysis of PD-1 and PD-L1 binding activity; in vitro screening and activity evaluation of PD-1/PD-L1 blocking antibodies; determination and ranking of the half-maximal inhibitory concentration (IC50) of candidate molecules; validation of the mechanism of action of immune checkpoint inhibitors; and parallel comparison of binding activity between different antibody or protein batches.
The main application scenarios of this product include: quantitative analysis of PD-1 and PD-L1 binding activity; in vitro screening and activity evaluation of PD-1/PD-L1 blocking antibodies; determination and ranking of the half-maximal inhibitory concentration (IC50) of candidate molecules; validation of the mechanism of action of immune checkpoint inhibitors; and parallel comparison of binding activity between different antibody or protein batches.
Question 5: What are the characteristics of TR-FRET compared with ELISA and SPR?
ELISA relies on coating and multiple washing steps, with many operational steps and results consistency affected by washing conditions; SPR and BLI can read binding kinetic parameters in real time but require dedicated sensor chips and instruments. TR-FRET belongs to a homogeneous wash-free system, which can directly complete incubation and reading in conventional multi-well plates, and a single experiment can obtain a concentration-effect curve, suitable for high-throughput comparison in the antibody screening stage; its signal is based on changes in intermolecular distance and has the ability to directly reflect the competitive binding of antibodies.
ELISA relies on coating and multiple washing steps, with many operational steps and results consistency affected by washing conditions; SPR and BLI can read binding kinetic parameters in real time but require dedicated sensor chips and instruments. TR-FRET belongs to a homogeneous wash-free system, which can directly complete incubation and reading in conventional multi-well plates, and a single experiment can obtain a concentration-effect curve, suitable for high-throughput comparison in the antibody screening stage; its signal is based on changes in intermolecular distance and has the ability to directly reflect the competitive binding of antibodies.
Product Information Overview
| Product Name | UniOne® TR-FRET Human PD1/PD-L1 Binding Kit (Catalog No.: UA086026, Specifications: 100T/500T/2500T/10000T) |
| Brand | UA-Bio |
| Detection Principle | TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous wash-free system |
| Detection Target | Interaction and binding activity of human PD-1 and PD-L1 proteins |
| Kit Components | Pembrolizumab (positive control, 5 μM), Tag1-PD-L1 protein (100×), Tag2-PD1 protein (100×), Anti-Tag1 Eu antibody (50×), Anti-Tag2 Ac antibody (12.5×), Detection buffer (10×) |
| Storage Conditions | -80℃ |
| Core Applications | Quantitative analysis of binding activity, screening and activity evaluation of blocking antibodies, IC50 determination, mechanism of action validation |
| Applicable Instruments | Multifunctional microplate readers equipped with time-resolved fluorescence (TR-FRET/HTRF) detection channels |
| Common Search Terms | PD-1/PD-L1 binding activity detection, PD-1 PD-L1 binding assay, PD-L1 blocking antibody screening, immune checkpoint inhibitor IC50, TR-FRET kit, Human PD1/PD-L1 Binding Kit, UA086026, UA-Bio UniOne |
If you need to conduct PD-1/PD-L1 binding activity detection or activity evaluation of blocking antibodies, you can search for the full product name "UniOne® TR-FRET Human PD1/PD-L1 Binding Kit" or the catalog number "UA086026" in the UA-Bio Product Center to obtain the product manual, experimental protocols, and supporting reagent information.
Product Information






